Barclays set a €81.00 ($94.19) price target on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a report published on Thursday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
Several other equities analysts have also commented on FME. Nord/LB set a €92.00 ($106.98) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Friday, May 3rd. Credit Suisse Group restated a buy rating and set a $90.00 target price on shares of Bayerische Motoren Werke in a research report on Thursday. Jefferies Financial Group restated a buy rating and set a GBX 99 ($1.29) target price on shares of in a research report on Friday, June 28th. Independent Research set a €74.00 ($86.05) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a neutral rating in a research report on Monday, June 17th. Finally, JPMorgan Chase & Co. restated a neutral rating on shares of SUZUKI MTR CORP/ADR in a research report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of €82.57 ($96.01).
Shares of Fresenius Medical Care AG & Co. KGaA stock opened at €67.00 ($77.91) on Thursday. The stock has a market capitalization of $20.45 billion and a price-to-earnings ratio of 10.43. Fresenius Medical Care AG & Co. KGaA has a 52 week low of €55.44 ($64.47) and a 52 week high of €91.74 ($106.67). The company has a debt-to-equity ratio of 100.05, a current ratio of 1.02 and a quick ratio of 0.67. The company has a 50 day moving average of €68.38.
Fresenius Medical Care AG & Co. KGaA Company Profile
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading: Overbought
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.